Charles River/$CRL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Charles River
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Ticker
$CRL
Sector
Primary listing
NYSE
Industry
Life Sciences Tools and Services
Headquarters
Employees
19,400
Website
Charles River Metrics
BasicAdvanced
$8.3B
-
-$0.62
1.50
-
Price and volume
Market cap
$8.3B
Beta
1.5
52-week high
$254.15
52-week low
$91.86
Average daily volume
845K
Financial strength
Current ratio
1.433
Quick ratio
0.938
Long term debt to equity
92.106
Total debt to equity
92.106
Interest coverage (TTM)
4.65%
Profitability
EBITDA (TTM)
888.742
Gross margin (TTM)
34.69%
Net profit margin (TTM)
-0.49%
Operating margin (TTM)
13.77%
Effective tax rate (TTM)
177.50%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
4.40%
Return on equity (TTM)
-0.67%
Valuation
Price to revenue (TTM)
2.159
Price to book
2.61
Price to tangible book (TTM)
-24.89
Price to free cash flow (TTM)
15.418
Free cash flow yield (TTM)
6.49%
Free cash flow per share (TTM)
11.003
Growth
Revenue change (TTM)
-2.16%
Earnings per share change (TTM)
-107.27%
3-year revenue growth (CAGR)
3.49%
10-year revenue growth (CAGR)
11.80%
3-year earnings per share growth (CAGR)
-57.76%
10-year earnings per share growth (CAGR)
-13.58%
What the Analysts think about Charles River
Analyst ratings (Buy, Hold, Sell) for Charles River stock.
Bulls say / Bears say
Charles River Laboratories has announced significant governance updates and a strategic review to enhance long-term stockholder value, including the appointment of four new directors and the formation of a Strategic Planning and Capital Allocation Committee. (criver.com)
The company has launched the Charles River Incubator Program, selecting six advanced therapy and technology developers to receive mentorship and access to its global facilities, potentially driving innovation and future growth. (criver.com)
Charles River is leveraging advanced technology to expedite oncology drug discovery and development, including the development of PDX-derived organoids and integration of AI/ML tools, positioning itself at the forefront of cancer research. (criver.com)
The FDA's decision to phase out animal testing poses a significant challenge to Charles River Laboratories' core business model, which has traditionally relied on animal testing services. (ainvest.com)
Insiders at Charles River Laboratories have sold a substantial stake in the company, with transactions totaling US$2.8 million, which may indicate potential concerns about the company's future performance. (simplywall.st)
The company has revised its full-year revenue forecast to a decline of 2.5% to 4.5%, a significant shift from the initially anticipated growth, reflecting challenges in maintaining its growth trajectory. (cweb.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Charles River Financial Performance
Revenues and expenses
Charles River Earnings Performance
Company profitability
Charles River News
AllArticlesVideos
Creightons shares fall 10% as cautious outlook tempers improved results
Proactive Investors·2 weeks ago
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Business Wire·2 weeks ago
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Charles River stock?
Charles River (CRL) has a market cap of $8.3B as of August 01, 2025.
What is the P/E ratio for Charles River stock?
The price to earnings (P/E) ratio for Charles River (CRL) stock is 0 as of August 01, 2025.
Does Charles River stock pay dividends?
No, Charles River (CRL) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Charles River dividend payment date?
Charles River (CRL) stock does not pay dividends to its shareholders.
What is the beta indicator for Charles River?
Charles River (CRL) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.